Advaxis launched part B of its ongoing combination Phase 1/2 study of its drug ADXS-PSA to treat late-stage prostrate cancer.
Advaxis launched part B of its ongoing combination Phase 1/2 study of its drug ADXS-PSA to treat late-stage prostrate cancer.